Ripril5 mg

Established / FDA-Approved Uses

• Hypertension: Ripril 5 mg is indicated for the treatment of high blood pressure, either alone or in combination with other antihypertensive agents, to lower blood pressure and reduce the risk of fatal and non-fatal cardiovascular events.
• Heart Failure Post-Myocardial Infarction: Ripril 5 mg is indicated to reduce the risk of death and to slow progression to severe/resistant heart failure in clinically stable patients who have signs of congestive heart failure within a few days after a heart attack (myocardial infarction).
• Reduction of Cardiovascular Risk: Ripril 5 mg is indicated in patients aged 55 years or older at high risk of a major cardiovascular event (such as those with a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes with an additional risk factor) to reduce the risk of myocardial infarction, stroke, and death from cardiovascular causes.

Guideline-Supported / Adjunct Uses

• Diabetic and Non-Diabetic Nephropathy: Ripril 5 mg is commonly used, as supported by clinical guidelines, to reduce proteinuria and slow progression of kidney disease in patients with diabetic and certain non-diabetic nephropathies, usually as part of a broader treatment plan.
• Left Ventricular Dysfunction / Chronic Heart Failure: Ripril 5 mg may be used as adjunct therapy (with diuretics, beta-blockers, etc.) in the long-term management of chronic heart failure with reduced ejection fraction.

A physician determines the appropriate indication and treatment plan for each patient based on individual clinical evaluation.

Each tablet/capsule contains Ripril 5 mg as the active pharmaceutical ingredient, commonly available in strengths of 1.25 mg, 2.5 mg, 5 mg, and 10 mg, along with pharmaceutically acceptable excipients.

Ripril 5 mg is an angiotensin-converting enzyme (ACE) inhibitor used in the management of hypertension, heart failure following a heart attack, and for reducing the risk of major cardiovascular events in high-risk patients. It works by relaxing blood vessels, which helps lower blood pressure and reduces the workload on the heart.

Ripril 5 mg is taken orally, usually once or twice daily depending on the indication, and is available in multiple strengths to allow individualized dosing. It is often used alone or in combination with other antihypertensive or heart failure medications.

Angiotensin-Converting Enzyme (ACE) Inhibitor; Cardiovascular / Antihypertensive Agent.

Ripril 5 mg is a prodrug that is hydrolyzed in the liver to its active metabolite, Ripril 5 mgat, a potent and long-acting inhibitor of angiotensin-converting enzyme (ACE).

Mechanism of Action

By inhibiting ACE, Ripril 5 mg blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This results in:

• Decreased plasma angiotensin II, leading to vasodilation and reduced peripheral vascular resistance.
• Decreased aldosterone secretion, which reduces sodium and water retention.
• Reduced degradation of bradykinin, a vasodilator, which may also contribute to the antihypertensive effect and to certain side effects (e.g., cough, angioedema).

Pharmacokinetics

After oral administration, Ripril 5 mg is rapidly absorbed and converted to Ripril 5 mgat. Peak plasma concentrations of Ripril 5 mgat occur within 2-4 hours. Ripril 5 mgat is highly protein-bound and is eliminated primarily via renal excretion, with a prolonged effective half-life allowing once- or twice-daily dosing.

Take Ripril 5 mg orally, with or without food, at the same time each day. Swallow tablets/capsules whole with water. Do not discontinue without medical advice, even if feeling well, as abrupt discontinuation can affect blood pressure control.

• Potassium-sparing diuretics, potassium supplements, salt substitutes: Concurrent use with Ripril 5 mg increases the risk of hyperkalemia; renal function and serum potassium should be monitored.
• Angiotensin receptor blockers (ARBs) or aliskiren: Dual blockade of the renin-angiotensin system with Ripril 5 mg plus an ARB or aliskiren increases the risk of hypotension, hyperkalemia, and renal impairment, and is generally not recommended; combination with aliskiren in patients with diabetes is contraindicated (see Contraindications).
• NSAIDs (including selective COX-2 inhibitors): May reduce the antihypertensive effect of Ripril 5 mg and increase the risk of renal impairment and hyperkalemia, particularly in elderly or volume-depleted patients.
• Lithium: ACE inhibitors such as Ripril 5 mg can reduce lithium excretion, increasing the risk of lithium toxicity; lithium levels should be monitored closely.
• Diuretics: Concomitant use can cause excessive hypotension, especially with the first dose; volume depletion should be corrected before starting Ripril 5 mg where possible.
• mTOR inhibitors / neprilysin inhibitors (e.g., sacubitril): Concurrent use increases the risk of angioedema; Ripril 5 mg should not be started until at least 36 hours after the last dose of a neprilysin inhibitor.
• Antidiabetic agents (insulin, oral hypoglycemics): Ripril 5 mg may enhance the blood-glucose-lowering effect, increasing the risk of hypoglycemia, particularly in the first weeks of combined treatment.

Common

• Persistent dry, non-productive cough
• Dizziness or lightheadedness (especially with the first dose)
• Headache
• Fatigue
• Hypotension
• Hyperkalemia (elevated blood potassium)

Serious (Less Common but Important)

• Angioedema (swelling of face, lips, tongue, throat, or extremities) - a potentially life-threatening reaction requiring immediate discontinuation and emergency care (see Precautions and Warnings).
• Acute kidney injury or worsening renal function, particularly in patients with pre-existing renal impairment or renal artery stenosis.
• Severe hypotension, especially in volume-depleted patients or those on diuretics.
• Rarely, liver dysfunction, blood dyscrasias (e.g., neutropenia), or severe skin reactions.

Patients should seek prompt medical attention for facial/throat swelling, difficulty breathing or swallowing, or signs of infection (fever, sore throat).

Pregnancy: Ripril 5 mg is contraindicated during pregnancy. Drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus when used during the second and third trimesters, including fetal hypotension, renal failure, skull hypoplasia, and death. When pregnancy is detected, Ripril 5 mg should be discontinued as soon as possible unless continued use is considered lifesaving for the mother.

Lactation: There is limited information on the presence of Ripril 5 mg in human milk. Because of the potential for serious adverse effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Ripril 5 mg, taking into account the importance of the drug to the mother; consult a physician before use while breastfeeding.

• Angioedema: Ripril 5 mg can cause angioedema of the face, extremities, lips, tongue, glottis, and/or larynx, which can occur at any time during treatment, particularly following the first dose. If angioedema involves the tongue, glottis, or larynx, or causes airway obstruction, emergency treatment and immediate discontinuation are required; patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk.
• Hyperkalemia: Risk is increased with renal impairment, diabetes, concomitant potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium. Periodic monitoring of serum potassium is advised.
• Hypotension: Symptomatic hypotension may occur, especially after the first dose, in volume- or salt-depleted patients (e.g., from diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting). Correct volume depletion before initiating therapy where possible.
• Renal function: Some patients may develop increases in blood urea and serum creatinine, particularly those with renal artery stenosis, pre-existing kidney disease, or heart failure. Monitor renal function periodically.
• Cough: A persistent, dry cough has been reported with ACE inhibitors, including Ripril 5 mg, and usually resolves after discontinuation.
• Anaphylactoid reactions: Rare reactions have been reported during desensitization treatments or with certain dialysis/apheresis membranes in patients receiving ACE inhibitors.
• Surgery/anesthesia: Ripril 5 mg may increase the risk of hypotension during major surgery or anesthesia with agents that lower blood pressure.

Overdose with Ripril 5 mg may cause pronounced hypotension, shock, electrolyte disturbances, and renal impairment. If an overdose of Ripril 5 mg is suspected, seek immediate medical attention or contact a poison control center right away. Do not attempt to manage an overdose at home. Management is supportive and should be carried out by qualified medical personnel, typically involving close monitoring of blood pressure, fluid and electrolyte status, and renal function in a medical facility.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Dose reduction of Ripril 5 mg is recommended in patients with renal impairment. For creatinine clearance less than 40 mL/min/1.73m², initial dose should be reduced (e.g., 1.25 mg once daily) with careful up-titration and monitoring of renal function and potassium; maximum daily dose may need to be limited.

Hepatic Impairment

Since Ripril 5 mg requires hepatic activation to Ripril 5 mgat, patients with significant liver impairment may have altered response; use with caution and close monitoring.

Elderly

Elderly patients may be more sensitive to the blood-pressure-lowering effects of Ripril 5 mg and may have age-related decreases in renal function; a lower starting dose and careful monitoring are generally recommended.

Pediatric

Safety and efficacy of Ripril 5 mg in pediatric patients have not been established; use in children is generally not recommended.

Ripril 5 mg is generally used long-term for chronic conditions such as hypertension and heart failure, as directed by a physician. Duration is individualized based on the treated condition, response, and ongoing medical evaluation; treatment should not be stopped abruptly without medical advice.

ACE Inhibitors; Antihypertensives; Cardiovascular Agents.

Ripril 5 mg is metabolized to Ripril 5 mgat, which inhibits angiotensin-converting enzyme, thereby reducing formation of angiotensin II. This leads to vasodilation, decreased aldosterone secretion, and reduced peripheral vascular resistance, lowering blood pressure and reducing cardiac workload.

Category D (FDA legacy pregnancy category; contraindicated in the second and third trimesters, and generally in pregnancy overall due to risk of fetal injury and death).

The safety and efficacy of Ripril 5 mg in pediatric patients (under 18 years) have not been established. Ripril 5 mg is therefore generally not recommended for use in children, and no established pediatric dosing regimen is available.